| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 640 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -57,780 | -74,560 | -66,650 | -47,010 | -26,450 |
| Net Income Growth | +22.51% | -11.87% | -41.78% | -77.73% | unch |
Rallybio Corporaton (RLYB)
0.6700 x 16 0.6955 x 5
Post-market by (Cboe BZX)
0.6700 -0.0300 (-4.29%) 03/21/25 [NASDAQ]
0.6700 x 16 0.6955 x 5
Post-market 0.6700 unch (unch) 16:00 ET
for Fri, Mar 21st, 2025
Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.
Fiscal Year End Date: 12/31